0001193125-23-145019.txt : 20230515 0001193125-23-145019.hdr.sgml : 20230515 20230515161609 ACCESSION NUMBER: 0001193125-23-145019 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230515 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TherapeuticsMD, Inc. CENTRAL INDEX KEY: 0000025743 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870233535 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-00100 FILM NUMBER: 23922600 BUSINESS ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-961-1900 MAIL ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AMHN, Inc. DATE OF NAME CHANGE: 20090930 FORMER COMPANY: FORMER CONFORMED NAME: CROFF ENTERPRISES INC DATE OF NAME CHANGE: 19970915 FORMER COMPANY: FORMER CONFORMED NAME: CROFF OIL CO DATE OF NAME CHANGE: 19920703 8-K 1 d481253d8k.htm 8-K 8-K
false 0000025743 0000025743 2023-05-15 2023-05-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 15, 2023

 

 

THERAPEUTICSMD, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Nevada   001-00100   87-0233535
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

951 Yamato Road, Suite 220

Boca Raton, FL 33431

(Address of Principal Executive Office) (Zip Code)

Registrant’s telephone number, including area code: (561) 961-1900

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

  

Trading
Symbol

  

Name of Each Exchange
on Which Registered

Common Stock, par value $0.001 per share   TXMD   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

The information provided in Item 7.01 of this Current Report on Form 8-K is incorporated in this Item 2.02 by reference.

 

Item 7.01

Regulation FD Disclosure.

On May 15, 2023, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01 and the information contained in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing.

The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in its expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Index

 

Exhibit No.

    Description
99.1    Press Release from TherapeuticsMD, Inc., dated May 15, 2023, entitled “TherapeuticsMD Announces First Quarter 2023 Financial Results”
104    Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 15, 2023     THERAPEUTICSMD, INC.
     

/s/ Marlan Walker

      Marlan Walker
      Chief Executive Officer
 EX-99.1 2 d481253dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

TherapeuticsMD Announces First Quarter 2023 Financial Results

BOCA RATON, Fla. – May 15, 2023 – TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023.

First Quarter 2023 Financial Results

Net Loss from Continuing Operations

 

  •  

Net loss from continuing operations was $2.3 million for the quarter ended March 31, 2023, or $0.24 per basic and diluted common share, compared to a net loss from continuing operations of $17.9 million, or $2.08 per basic and diluted common share, for the comparable period in 2022.

License and Service Revenues from Continuing Operations

 

  •  

License and service revenues from continuing operations, which are revenues related to license agreements, were $0.4 million for the quarter ended March 31, 2023, compared to $0.7 million in license and service revenue related to sales to other licensees for the first quarter of 2022. This decrease was due to a decrease in sales to licensees as a result of the Company’s transformation and transition from a manufacturing and commercialization business to a royalty-based business, partially offset by the license revenue recognized during the first quarter from the Mayne License Agreement.

Total Operating Expenses from Continuing Operations

 

  •  

Total operating expenses from continuing operations for the first quarter of 2023 were $3.1 million, a decrease of $14.8 million, or 82.8%, compared to the first quarter of 2022. This decrease was due to the transition of our business from a manufacturing and commercialization business to a royalty-based business with limited infrastructure.

Discontinued Operations

 

  •  

Net loss from discontinued operations was $1.3 million for the quarter ended March 31, 2023, or $0.13 per basic and diluted common share, compared to a net loss from discontinued operations of $31.1 million, or $3.62 per basic and diluted common share, for the comparable period in 2022.

The Company continues to wind down its former commercial operations and to focus on reducing costs.

About TherapeuticsMD

TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar

expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: whether Mayne Pharma will be successful at commercializing the products that it licensed and acquired from TherapeuticsMD; whether the company is successful in winding down its operations and the costs associated therewith, including the company’s ability to obtain any additional financing necessary therefor and any adjustments to the net working capital purchased as part of the Mayne Pharma transaction; whether the company is successful in identifying strategic pathways to create additional shareholder value; the company’s ability to remain listed on Nasdaq; the impact of product liability lawsuits; the impact of leadership transitions; and the volatility of the trading price of the company’s common stock.

CONTACT:

 

Marlan D. Walker    Lisa M. Wilson

Chief Executive Officer

561-961-1900

   

In-Site Communications, Inc.

212-452-2793

lwilson@insitecony.com

 EX-101.SCH 3 txmd-20230515.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 txmd-20230515_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 txmd-20230515_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g481253g0516001456598.jpg GRAPHIC begin 644 g481253g0516001456598.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#WZDXKDO&W M@^Y\5_8?L^IM9?9O,W84G?NV^XZ;?UKS?Q7X!O\ POH4FIMKTMP$=4\L*5SN M..N:VITHS27-J<]6K.%VHW2/=I)Z5XOH'PVU# M7="L]3'B"2$7,>_RRA.WGUW5TMUX9G\+?"_Q#9W%^;QI5>82%2, JHQU/]W] M:1U M1%FE)9C@#YC7:V]Y:W0)M[B*8#KY;AL?E6S*J[F( '4F@+CZ*C$B M%-X=2GJ#Q38;B*X7?#*DBYQE&!&?PH%@)ZTR>\MK7!N+B*('H9'"Y_.BP718HJ..5)8P\; MJZ-R&4Y!I^:!BT57N+RVM0#<7$4.>GF.%S^=/CFCF021.KH>C*<@T"NMB6BH MWE2/[[JN?[QQ3\T#"BF-*B$!G4$] 3C-;C/3/'ZT8-WY58ZBBU@N MF-S]*45Y!JFKWNC_ ! U"^@\QX8)5\Y,\;"%!_7'XXKU>RO(;^SBN[=P\,J[ ME8>AJY0<4F;>-[=K[Q MMI-CY\L4<\85C&<$98U=_P"%=/$-]IKE[',/NLQ_PQ3Y%9-LCZU4$;^*T\0'[582G:ET!DC\>_T-=;>6$-]J.GWBPQRJA),G!^7 M:2OX9.:3C;F372U+T-(3 ]:_Z]FIGP]_Y$'1O^N']33_'W_(A MZU_UZM3_ .7WS)7\#Y?H>5^"/"FI>+]&6*YU"6UT:TD98TBZR2'DG\,XJ7Q3 MX-OO "0:YHNISM''(%?<<%">!G'!4]/QKN/A)_R(-O\ ]=I?_0JG^*@_XMWJ M/^]#_P"C5KH=67MN7I> M:!X9U/XC&37=>U":.T=RL$49X(!YP.R@\?458O8I9?V?K8QY(0(S@?W1-_G\ MJJ>$]!\8ZCX:L[C2?$RV]F58)"/X"&.1T]?YT1BH1DT[:V"4G.44U?2XOB'P MOJ7PY\K7="U"=[9'"S1R'@9/&?53TKKO%>KQZU\);K5+-P >5.]8L?G9G9AGU M.#C'M7I5EX+N]*\#W>AV&J2)=2N9$N1P5)(X^F!C\:9\)[6.'P#9RHN'N)99 M)#ZD.5'Z**K_ !2\5WOAW2[2VTYS'=7K,/- Y15QG'OEA2G*4ZG)'N.G",*7 MM)ZZ&5'\'[4Q@WVO737!ZE<8_7FLW1YM5^'WC^UT*YO7NM.OF4+DG'SG:K<] M"&&#[5IVGPHO;BW6;4_$=X+MQN<1,2H/IDFN7USP[+X:\>^'K234Y;[?<0NI ME^\@\T_GT_QQHMW;EBT$,01WK.:%/"5M$Y'FO M=J8QWX5LG]?UKG/']MI71FNP)$C5NBGH3^&,#TJI?VVJ?"G7;.ZM[R6[T6Y;;)&Y M].H(Z9QD@_6M'3_#7CNZTVUGM/%B_9I(E:+!/"D<=O2H]4^'GC/6+9;?4O$4 M-S"K[E23. V",]/0G\ZI2]ZTI*W8GD?+>,7?N+\:+G?INAS02G9(TC*5;&05 M4BO6(/\ 41_[H_E7C?Q7LI=/\*^&+.5@\EM$87<="RHH_7%>Q6SK):0NC!E9 M 5(Z$8K&JE[*-O,Z*+?M97\CRSXJ2.GB[PN%=E!DY )&?WB59^+7AE+C3)_$ M9NYE>VABA$ ^XV9<9/O\_P"@JE\594/C3PS$&&]'#,/0&1TN<1X7^&,&O>&;+4FU>\@:X1B8TQA?F(X_*NK^ M*2-:_#MHT=LQRPJ&!P3@@5I_#?\ Y)]I'_7-O_0VK/\ BY_R(4__ %WB_P#0 MJGGE*M9]&4H1C0NNJ&6GB1/#/PETS4Y!YDWV6-(D8_?D(X'\S^%=U#"9&!5C[>U=AX,T35-!TF2TU346O7$I\HDY"(. !G\_QKA)/ OC#P ML&F\/ZPUQ"G(AW8) [8/'X"NL^'GC&;Q7IUPMY$J7UHRK+M& P.<''8\'BKJ M\THW3NC.CRQFDU9F;IMI#?\ Q'\16MP@>*6 JZGN#LIWAF[F\*^(9O#6H.3; M2MOM)&Z'/0?C_,>]2Z#_ ,E3UW_KE_\ $5M>,/#G]O:6&@ %];G? ^<$_P"S MGW_F!4.2ORO9G+3I2Y'5I_%%OYZ['/:BS^./%:Z;"Q_LBP;=.RGB1NX_H/Q- M/BC6+XOK'& J+; *!T V5U/AG0H_#^D1VB@&8_--)_>;_"N8_P":R?\ ;O\ M^R4)IMI;6"I2<5"<_B)+6>7XBZ'*D+M& MH7FXY _+%'_+O4G1XSW>BU_0Z+%&*6BLSN$KD?B3I=[K/@Z:SL M(&GN&EC8(O7 8$UUU%.,G&2:)G%2BXLP?!=E<:=X.TRSNXC%<10[70]0 M,;.XU'PAJEG:QF2>:W940=2:W.*.*?,^;F%R+DY3D?AMI=[H_@Z"SU"!H+A9 M9&*-UP6R*F^(>FWFK>"KVRL86FN)#&51>IQ(I/Z"NHHZT^=\_.+V:Y.0Y;PG MHKQ?#^ST?5;;:3 \4T+>A9OZ&N(BT+QE\/[R<:%'_:>ERMN$>-Q'U Y!]QD5 M[!1Q51K--WV9$J":23LT>17+_$3QB!8O9G2+-B/-<@QG'U/)'T%=CXIT>]N/ MAWYR_P /M.N])\$6 M%E?0M#<1F7'3<7"C8+DJ0#VR2.#]+ MM(UC4HS=3-<12SF,C; JR [?P&3Q7M?%%:*NT[Q21D\-?XFV>-?%.T74?B#H M%B[%4N4B@8CJ TI4G]:M13?$3PC%_9T-D-5M(_E@F5"Y"]NG(^A_.NB\4^#+ M_7/&NBZU;SVR6]B\32)(S!FV2[SC (Z>I%=S5.LE&,=R%0;G*5['D6G^#O$G MC+7(=4\7?N;2'&RVZ%AUVA?X1QR3S_3TC7M#M?$&B3Z7V.5^A%68;+Q] MXPU&VDU%FT6Q@D$F$^5LCVZL?KQ7J]*:MU_)7[D+#].9V['+^-_"H\5>'38I M*$N87$L#MTW $8/L037!:9J7Q(\/VJ:0NCM[,D1*+CL>:[.DIRK7DI M6"-"T7&[LSE=,\.K??#FRT+5H60FT2.1?XD8 8(]P>:X:UT_QYX">2TTV#^T M]-+DHJJ7Q] .5/KVKV3 HI1K-7NKIA*@G:SLT>0FP\?>-KR!=1+:/81.'.T% M&R#D'&U,I)9JYY0WB3XE&)K,^'Q]H/RBX$1VCWZX_6NC^'7A&Y\+Z;ATO%. M,N4G$4%6BE>UG XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 15, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000025743
Document Type 8-K
Document Period End Date May 15, 2023
Entity Registrant Name THERAPEUTICSMD, INC.
Entity Incorporation State Country Code NV
Entity File Number 001-00100
Entity Tax Identification Number 87-0233535
Entity Address, Address Line One 951 Yamato Road
Entity Address, Address Line Two Suite 220
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33431
City Area Code (561)
Local Phone Number 961-1900
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol TXMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d481253d8k_htm.xml IDEA: XBRL DOCUMENT 0000025743 2023-05-15 2023-05-15 false 0000025743 8-K 2023-05-15 THERAPEUTICSMD, INC. NV 001-00100 87-0233535 951 Yamato Road Suite 220 Boca Raton FL 33431 (561) 961-1900 false false false false Common Stock, par value $0.001 per share TXMD NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d481253d8k.htm d481253dex991.htm txmd-20230515.xsd txmd-20230515_lab.xml txmd-20230515_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d481253d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d481253d8k.htm" ] }, "labelLink": { "local": [ "txmd-20230515_lab.xml" ] }, "presentationLink": { "local": [ "txmd-20230515_pre.xml" ] }, "schema": { "local": [ "txmd-20230515.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "txmd", "nsuri": "http://imetrix.edgar-online.com/20230515", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d481253d8k.htm", "contextRef": "duration_2023-05-15_to_2023-05-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d481253d8k.htm", "contextRef": "duration_2023-05-15_to_2023-05-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imetrix.edgar-online.com//20230515/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-145019-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-145019-xbrl.zip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end